{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.21","upperLimit":"0.67","value":"0.43"},{"groupId":"OG001","lowerLimit":"0.29","upperLimit":"0.77","value":"0.54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Proportion of evaluable patients with complete or partial tumor response by RECIST 1.1 criteria.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (ORR = CR + PR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV","id":"OG000","title":"Arm I (Paclitaxel, Carboplatin)"},{"description":"Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nBleomycin Sulfate: Given IV\n\nCisplatin: Given IV\n\nEtoposide Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Arm II (Bleomycin Sulfate, Etoposide Phosphate, Cisplatin)"}],"paramType":"NUMBER","populationDescription":"Patients with at least one target lesion by RECIST 1.1 criteria and and at least one CT tumor assessment","reportingStatus":"POSTED","timeFrame":"Median followup time was 48 months.","title":"Tumor Response Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}